Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK

Payment Information We Accept Visa, Mastercard, American Express and Discover

 

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Lilly Partners with Regor Therapeutics for Metabolic Drug Discovery

Here is a brief preview of this blast: Lilly announced it has entered into a multi-year research agreement with Regor Therapeutics Group for the discovery, development, and commercialization of novel therapies for metabolic disorders. For context, Regor Therapeutics Group (view website) is a Chinese-based pharma company using Computer Accelerated Rational Discovery (CARD) to develop new medicines. Interestingly, the press release states, "Regor's technology will also allow Lilly to further accelerate innovation and deliver breakthrough therapies in obesity and diabetes," suggesting the partnership is broader than obesity and diabetes. Below, FENIX provides thoughts and insights on the Regor partnership.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.